Pfizer has a pill it's developing called danuglipron, which is in early-stage trials but has demonstrated that it's ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Pfizer ( PFE) raised its full-year guidance by $1.5 billion and posted strong third quarter earnings Tuesday. The company now ...

Doubling down on the bad news, Pfizer's journey into the weight loss drug market has fallen flat, as its twice-daily obesity-fighting pill danuglipron triggered nausea and other stomach issues in ...

Pfizer has yet to distinguish itself in the increasingly competitive race for weight-loss primacy, and is continuing to work on a weight-loss pill. Bourla said in the May interview that the ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Paxlovid, its antiviral pill, brought in $2.7 billion in sales ... FTC sues drug middlemen for allegedly inflating insulin ...

Novo Nordisk and Eli Lilly are also working on developing their own next-gen weight loss drugs. Pfizer seems to be primarily focused on incretin pills. Weight loss medications that already on the ...

Meanwhile, its weight-loss pill, danuglipron, stumbled in early trials — raising questions of whether Pfizer will get any piece of the weight-loss market pie before robust competition builds up.

Pfizer (PFE) CEO Albert Bourla is bullish about the company's near-term outlook after a flubbed attack campaign from activist investor Starboard Value earlier this month. "We have launched an ...